热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　康宁杰瑞制药-B（09966）公布，预期该集团将于截至2024年12 月31日止年度取得利润不少于人民币1.5亿元，而截至2023年12月31日止年度则取得亏损约人民币2.106亿元。此乃公司首次实现年度盈利。

　　公告称，本公司于报告期内转亏为盈，主要基于三项授权合作和销售收入。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.